Cancer clinical trials
Search all available trials by condition
NCT04442724 - Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
NCT05614739 - FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT07218380 - A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT06770582 - Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
NCT06465069 -A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT07097142 - Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NCT04752722 - LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT05951179 - Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
NCT03216525 - Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
NCT07000084 - Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
NCT05715684 - Patient-Centered Surgical Prehabilitation
NCT06319820 - A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT07104799- Momelotinib During and After HCT in Myelofibrosis
NCT06910969 - Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
NCT03394365 - A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
NCT06472089 - BMT-CARE: Psychosocial Intervention for Transplant Caregivers
NCT06707493 - Ivosidenib as Post-HSCT Maintenance for AML
NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT06253871 - A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT05633654 - Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT06492616 - A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT05608252 - VS-6766+Abema+Fulv in Met HR+/HER- BC
NCT06888388 - Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer
NCT07209436 - Impact of Pectoral Versus Paravertebral Blocks on Pain and Physical Well-Being in Implant-Based Breast Reconstruction
NCT06926868 - A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06638307 - A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
NCT06324357 - Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT05696626 - Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05563220 - Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
NCT04893109 - ATEMPT 2.0: Adjuvant T-DM1 vs TH
NCT06239467 - First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT05514717 - A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
NCT04115306 - Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
NCT05232916 - Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT06757634 - Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT05304962 - FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
NCT06908928 - A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
NCT04150042 - SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
NCT03488693 - Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT04230109 - Sacituzumab Govitecan In TNBC
NCT02290834 - Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
NCT03990896 - Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT04787042 - Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
NCT04553770 - Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT04802759 - A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
NCT06369285 - A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06760637 - Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06184750 - Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
NCT06896474 - SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
NCT06488378 - Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
NCT04724499 - Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy
NCT06322888 - Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
NCT05795101 - TRUDI: TDXD+Durva in HER2+/Low IBC
NCT04986579 - Scalp Cooling in MBC
NCT04030507 - Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
NCT04981119 - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
NCT06795529 - Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer
NCT04981119 - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
NCT03816345 - Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
NCT06201416 - A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Rheumatoid Arthritis
NCT05646576 - Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive Cellular Therapy
NCT05952804 - IVIG for Infection Prevention After CAR-T-Cell Therapy
NCT05020444 - TriPRIL CAR T Cells in Multiple Myeloma
NCT06297226 - Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT05660369 - CARv3-TEAM-E T Cells in Glioblastoma
NCT05640999 - Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
NCT06366347 - ALPINE: Maintenance Letrozole/Abemaciclib
NCT06369155 - Azenosertib in Uterine Serous Carcinoma: Biomarker Study
NCT06518564 - Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
NCT04839614 - Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
NCT04956640 - Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT07351071 - Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections
NCT04929223 - A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT07284849 - A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT03482102 - Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
NCT07359820 - A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
NCT04291105 - Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
NCT06541990 - Psychoeducational Intervention for Patients With Hepatocellular Carcinoma
NCT07006727 - Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
NCT03659448 - Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
NCT07217704 - Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT05652686 - A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
NCT07300150 - A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT05692024 - Coffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
NCT06302621 - Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
NCT02584244 - Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
NCT06265272 - Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
NCT07020221 - A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT06655246 - A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
NCT04656041 - Folfox+Irinotecan+Chemort In Esophageal Cancer
NCT07095517 - Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
NCT07070466 - Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
NCT06412198 - A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
NCT03803553 - Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
NCT06917079 - BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT03830801 - Pilot Study for OCT Guided In Vivo Laser Capture Microdissection for Assessing the Prognosis of Barrett's Esophagus
NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
NCT06040541 - Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06084234 - National Liver Cancer Screening Trial
NCT06123338 - A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
NCT04924075 - Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
NCT07094113 - AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT06160752 - Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
NCT03801876 - Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
NCT06586515 - MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06259292 - Comprehensive HHT Outcomes Registry of the United States (CHORUS)
NCT06445062 - Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06914128 - A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors
NCT05080673 - Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NCT05355701 - A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
NCT06565052 - The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial
NCT02947971 - Pilot Study for TCE Imaging of the Esophagus Using an OFDI Capsule With a Compact Imaging System
NCT07219537 - A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule
NCT06064877 - A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT04534205 - A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
NCT03493425 - Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
NCT05668962 - Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
NCT04370587 - A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
NCT04620187 - Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
NCT07405645 - Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy
NCT07465276 - Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
NCT06805617 - A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
NCT04900623 - Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
NCT06940180 - Toripalimab With Chemotherapy for Sinus Cancer
NCT05926765 - A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
NCT06239220 - PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
NCT05726370 - Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
NCT04883671 - Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial
NCT05553782 - Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
NCT05842603 - I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
NCT04647227 - SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
NCT04176198 - A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
NCT06465953 - Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
NCT06343805 - A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
NCT02074839 - Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT06773195 - A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
NCT04227847 - A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
NCT06817395 - Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
NCT06419634 - Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT04644211 - Ruxolitinib in Thrombocythemia and Polycythemia Vera
NCT06297941 - Study of REM-422 in Patients With AML or Higher Risk MDS
NCT05143996 - CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT07441694 - Study of INCA036978 in Participants With Myeloproliferative Neoplasms
NCT04614558 - Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
NCT03850574 - Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT03830320 - Positron Emission Tomography (PET) Imaging of Thrombosis
NCT06948318 - A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT05715047 - Intervention for Fatigue in HCT Recipients
NCT06561347 - Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
NCT01351545 - A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
NCT06096116 - Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
NCT06517641 - Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
NCT06722235 - A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT04278404 - Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04910685 - (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
NCT04541654 - Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
NCT06487247 - HEME Home Transfusion Program
NCT07148180 - A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
NCT06059391 - CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
NCT06138587 - Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
NCT05335928 - Abatacept in Immune Checkpoint Inhibitor Myocarditis
NCT04945707 - Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)
NCT05327686 - Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NCT07011719 - Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT06401330 - A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT07397611 - Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
NCT07123090 - A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
NCT04988555 - A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT05735184 - A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
NCT03319901 - Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
NCT04801797 - Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
NCT03959085 - Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT06440135 - Ziftomenib Maintenance Post Allo-HCT
NCT06578247 - Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06472128 - Novel Digital Application for Patients With Acute Leukemia
NCT04811560 - A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04293562 - A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
NCT06456463 - A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
NCT05546580 - Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
NCT03331198 - Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
NCT05429632 - Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
NCT04067336 - First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT05237258 - Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
NCT03824483 - Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
NCT04560322 - Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
NCT06152809 - CIML NK Cells With Venetoclax for AML
NCT06043674 - Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
NCT06707493 - Ivosidenib as Post-HSCT Maintenance for AML
NCT05592626 - A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT05265429 - Biology of Young Lung Cancer Study: The YOUNG LUNG Study
NCT04712877 - Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers
NCT03191149 - Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT06706076 - A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
NCT04165798 - KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
NCT04165070 - KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
NCT06793215 - A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT03535545 - Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
NCT03029325 - Molecular and Genetic Analysis of Lung Cancer
NCT06910956 - Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT
NCT04900935 - Patient-centered, Optimal Integration of Survivorship and Palliative Care
NCT06196008 - Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
NCT06716580 - EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
NCT00471978 - DNA Analysis of Blood and Tissue from Patients with Lung Cancer
NCT07227623 - A Digital Health Intervention to Improve Physical Function and Wellness of Lung Cancer Survivors
NCT07315113 - Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
NCT05784922 - Health Opportunities and Promoters of Equitable Screening for Lung Cancer
NCT04410796 - Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
NCT05098132 - Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
NCT05898594 - Lung Cancer Screening in High-risk Black Individuals
NCT06931626 - Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
NCT06427954 - Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer
NCT04485286 - Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
NCT06922591 - Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06623422 - A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT07132190 - Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
NCT06987890 - Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy
NCT04155034 - S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
NCT06538376 - Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
NCT05730816 - MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
NCT03623958 - Image Guided VATS vs. VATS Resection
NCT03683680 Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
NCT06521554 - A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
NCT05587439 - Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
NCT04789486 - Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
NCT03460977 - A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977 - A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT05978141 - A Registry for People With T-cell Lymphoma
NCT06067347 - A Global Study of the PETAL Consortium
NCT05607420 - Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
NCT06550141 - Emapalumab Prevention of CAR-T Cell Associated Toxicities
NCT06854003 - BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
NCT04906096 - Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
NCT06475235 - Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
NCT04104776 - A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT05549297 - Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
NCT06581406 - A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
NCT05428007 - Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
NCT07364474 - Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
NCT05779423 - Cryoablation+Ipilimumab+Nivolumab in Melanoma
NCT06743126 - SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT07015190 - Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT06664151 - A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
NCT05922501 - Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
NCT05651932 - A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
NCT04176718 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
NCT06138275 - Elranatamab in R/R Multiple Myeloma
NCT06413498 - A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT05201781 - A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT07266441 - A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT02343042 - Selinexor and Backbone Treatments of Multiple Myeloma Patients
NCT04973605 - A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
NCT07032714 - Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
NCT06832865 - ELISA in Relapsed/Refractory MM
NCT06518551- Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
NCT06215118 - A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
NCT06483139 - Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
NCT07130786 - Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
NCT06552260 - A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
NCT03922555 - ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
NCT07100990 - Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
NCT03761121 - Developing Fast Pediatric Imaging
NCT06273176 - The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
NCT06283927 - The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
NCT05013892 - NTS-WBRT in Brain Metastases
NCT03382977 - Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
NCT05976490 - NeuroPathways Intervention for Brain Tumor Patients
NCT03126916 - Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
NCT05463848 - Surgical Pembro +/- Olaparib w TMZ for rGBM
NCT05303519 - SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT06172296 - Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT04708171 - The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections
NCT05580562 - ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT02977780 - INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
NCT06649851 - G-CSF After Chemo-radiation in Patients With Glioblastoma
NCT03286335 - Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
NCT06099743 - ASCENT Intervention for Brain Tumor Patients
NCT04684368 - A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
NCT02896335 - Palbociclib and Pembrolizumab In Central Nervous System Metastases
NCT07420751 - Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis
NCT05684692 - Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
NCT05503797 - A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT07233408 - Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy
NCT05382338 - A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
NCT06262113 - A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
NCT06146725 - The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
NCT06146738 - The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
NCT06118723 - The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
NCT02112617 - Phase II Study of Proton Radiation Therapy for Neuroblastoma
NCT04166409 - A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
NCT03970447 - A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
NCT02523014 - Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT06835803 - Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial
NCT06917885 - CUE-102 in Recurrent Glioblastoma
NCT06000787 - MCT for the Harvard/UCSF ROBIN Center
NCT05503264 - A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NCT04135807 - Implantable Microdevice In Primary Brain Tumors
NCT04033497 - Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
NCT06787612 - Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
NCT03564340 - Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT07023627 - A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT04794322 - Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
NCT06710548 - REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
NCT03675893 - RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
NCT06469281 - A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancer
NCT06888921 - A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
NCT06690775 - CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer
NCT06964009 - DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT06321484 - Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
NCT05470920 - Genetic Testing Decision Aid
NCT04789486 - Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
NCT04970056 - Pancreatic Cancer Early Detection Consortium
NCT05968326 - A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT07216521 - Intent of Surgery for IPMN
NCT07024615 - A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
NCT06122896 - Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
NCT05470920 - Genetic Testing Decision Aid
NCT03067181 - Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT02402244 - Project: Every Child for Younger Patients With Cancer
NCT03750513 - LET Optimized IMPT in Treating Pediatric Patients With Ependymoma
NCT01696721 - Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy
NCT03460977 - A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT05899361 - A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
NCT04134260 - Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NCT07427043 - Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
NCT06398639 - Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer
NCT05519449 - Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
NCT04472338 - Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
NCT06800313 - A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT06579417 - ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer
NCT06691984 - Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT05129605 - Prostate Cancer Genetic Risk Evaluation and Screening Study
NCT06862856 - Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
NCT06801236 - Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
NCT05804318 - Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
NCT06040125 - Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
NCT06202820 - CV CARE: CardioVascular Care in PC Patients
NCT06957691 - Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
NCT05946213- Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT06302595 - MRI Guided Prostate Biopsy
NCT05765500 - RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
NCT06807086 - Efficacy of Synchronous, Virtual Cognitive Behavioral Therapy for Insomnia Across Phases of Cancer Survivorship
NCT05674357 - Training in Evidence-based Treatments in Psycho-Oncology
NCT06181643 - Innovating CBT-I for Cancer Survivors: An Optimization Trial
NCT06172907 - A Dyadic Intervention for Young Adult Patients With Cancer and Their Partner Caregivers
NCT07139769 - Adapting Psychosocial Resiliency Intervention for Parents of Adolescents and Young Adults With Cancer
NCT07102797 - ActiveGirls: Physical Activity, Hormone Health, and Diabetes Risk in Early Adolescence
NCT06915662 - Pain Outcomes After Digital Amputation Using Tulavi Allay™ Nerve Cap
NCT01521741 - Prospective Screening for Breast Cancer-related Lymphedema
NCT06136546 - Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
NCT06094257 - Prospective Study of Sensation and Satisfaction in Cancer and Transgender Mastectomy Patients
NCT04301765 - Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
NCT06183437 - The STOP-MED CTRCD Trial
NCT06068075 - Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD
NCT05691478 - A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
NCT05304585 - Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
NCT05235165 - Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
NCT01659203 - Proton or Photon RT for Retroperitoneal Sarcomas
NCT04752137 - Intraoperative Tumor Margin Identification With ICG Dye Imaging
NCT03295981 - Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
NCT06088290 - Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
NCT06812052 - Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery
NCT07104331 - SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
NCT02792270 - Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
NCT06720142 - Mg OSTEOCRETE Post-Treatment Outcomes
NCT06709495 - Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
NCT03838718 - REtroperitoneal SArcoma Registry: an International Prospective Initiative
NCT04389632 - A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04585750 - The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT06238479 - A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors (EXCEED)
NCT07090499 - A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT06157892 - A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT05768139 - First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT06562192 - Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06239194 - Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06395519 - A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06827613 - A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
NCT06625775 - Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT07114601 - A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07109726 - A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT05579366 - Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05919264 - FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT05669430 - A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT03526835 - A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT04900818 - A Phase 1 Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors
NCT03645928 - Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
NCT05538130 - A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT03093116 - A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT04683250 - Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
NCT06171750 - Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
NCT06561685 - A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT04665206 - Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
NCT06425926 - Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
NCT05533697 - Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
NCT03686124 - ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
NCT07070232 - A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT06672185 - ARC101 in Advanced Solid Tumors
NCT06736704 - SNV4818 in Participants With Advanced Solid Tumors
NCT06724016 - Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
NCT06959706 - Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
NCT06797336 - A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
NCT05076396 - PM14 Administered Intravenously to Patients with Advanced Solid Tumors
NCT04130516 - Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
NCT05384626 - A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT05732831 - Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
NCT06597721 - ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
NCT06795412 - Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
NCT04896697 - Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
NCT06781983 - Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
NCT04104776 - A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas